DMET TM  (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

Mariamena Arbitrio; Maria Teresa Di Martino; Francesca Scionti; Giuseppe Agapito; Pietro Hiram Guzzi; Mario Cannataro; Pierfrancesco Tassone; Pierosandro Tagliaferri

doi:10.18632/oncotarget.9927

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

DMET^TM (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

Mariamena Arbitrio, Maria Teresa Di Martino, Francesca Scionti, Giuseppe Agapito, Pietro Hiram Guzzi, Mario Cannataro, Pierfrancesco Tassone _ and Pierosandro Tagliaferri

PDF | HTML | How to cite

Oncotarget. 2016; 7:54028-54050. https://doi.org/10.18632/oncotarget.9927

Metrics: PDF 2107 views | HTML 4828 views | ?

Abstract

Mariamena Arbitrio1, Maria Teresa Di Martino2, Francesca Scionti2, Giuseppe Agapito3, Pietro Hiram Guzzi3, Mario Cannataro3,4, Pierfrancesco Tassone2,* and Pierosandro Tagliaferri2,*

1 ISN-CNR, Roccelletta di Borgia, Catanzaro, Italy

2 Department of Experimental and Clinical Medicine, Medical Oncology Unit, Mater Domini Hospital, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy

3 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy

4 ICAR-CNR, Cosenza, Italy

* These authors have contributed equally to this work

Correspondence to:

Pierosandro Tagliaferri, email:

Pierfrancesco Tassone, email:

Keywords: pharmacogenomics, single nucleotide polymorphism, DMETTM, ADME genes, biomarkers

Received: March 14, 2016 Accepted: May 29, 2016 Published: June 09, 2016

Abstract

In the era of personalized medicine, high-throughput technologies have allowed the investigation of genetic variations underlying the inter-individual variability in drug pharmacokinetics/pharmacodynamics. Several studies have recently moved from a candidate gene-based pharmacogenetic approach to genome-wide pharmacogenomic analyses to identify biomarkers for selection of patient-tailored therapies. In this aim, the identification of genetic variants affecting the individual drug metabolism is relevant for the definition of more active and less toxic treatments. This review focuses on the potentiality, reliability and limitations of the DMETTM (Drug Metabolism Enzymes and Transporters) Plus as pharmacogenomic drug metabolism multi-gene panel platform for selecting biomarkers in the final aim to optimize drugs use and characterize the individual genetic background.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9927

Publication Alerts

Reviews:

DMETTM (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

Abstract

DMET^TM (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine